Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Younger Adults With Relapsed/Refractory B-cell ALL (ALL 001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03962465
Recruitment Status : Recruiting
First Posted : May 24, 2019
Last Update Posted : September 11, 2020
Sponsor:
Collaborators:
Pfizer
Vanderbilt University
University of Wisconsin, Madison
Virginia Commonwealth University
Information provided by (Responsible Party):
Michael Douvas, MD, University of Virginia

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 30, 2022
Estimated Study Completion Date : November 30, 2025